Date: Saturday, December 12, 2009
Time: 7 am - 9 am
Poster presentation (4049)
The 70-Gene Profile (MammaPrint) Is an Independent Predictor of Breast Cancer Specific Survival for Women 65 Years of Age or Older
Bedard PL, Mook S, Knauer M, Durbecq V, Bernard-Marty C, Glas AM, Cardoso F, van 't Veer LJ. Jules Bordet Institute, Brussels, Belgium; Netherlands Cancer Institute, Amsterdam, The Netherlands; TRANSBIG Consortium, Brussels, Belgium; Agendia BV, Amsterdam, The Netherlands
Date: Sunday, December 13, 2009 Time: 7 am - 8:30am Poster presentation (6131) Molecular Subtype Profile Reveals Therapy Predictive Power
de Snoo FA, Krijgsman O, Roepman P, Bender RA, Glas AM. Agendia BV, Amsterdam, The Netherlands; Agenda, Inc., Huntington Beach, CA..
Date: Sunday, December 13, 2009
Time: 7 am - 8:30am
Poster presentation (6146)
Biological Functions of Genes in the 70-Gene MammaPrint Tumor Expression Profile Reflect Molecular Mechanism of Tumor Metastasis
Glas AM, Tian S, Roepman P, Krijgsman O, Van 't Veer LJ, de Snoo F. Agendia BV, Amsterdam, The Netherlands; The Netherlands Cancer Institute, Amsterdam, The Netherlands.
MammaPrint is the first and only breast cancer recurrence test cleared by
the U.S. Food and Drug Administration (FDA). FDA clearance under the in vitro
diagnostic multivariate index assay (IVDMIA) guidelines requires clinical and
analytical validation and reporting systems to ensure patient safety issues
are addressed. Highly accurate, MammaPrint identifies pat
|SOURCE Agendia B.V.|
Copyright©2009 PR Newswire.
All rights reserved